Suomen Terveystalo Oy — Clinical Trial Site

42 Registered trials

12 Currently recruiting

Organisation

Suomen Terveystalo Oy

Location

Helsinki, Finland

Identifier

ORG-100045396

Address

Valimotie 21, 00380, Finland

Departments

2krs. H216
4504: Internal Medicine
6901: General Practice
Clinical Research
Clinical Trials
Department of Clinical Trials
Helsinki Sleep Clinic
Helsinki Sleep Clinic Terveystalo Healthcare
Ihotaudit ja allergologia
Jyväskylä
N/A
NA
Psychiatry
Suomen Terveystalo Oy
Terveystalo Biobank and Clinical Research
Terveystalo Helsinki Uniklinikka
Terveystalo Clinical Research
Terveystalo Helsinki
Terveystalo Helsinki Sleep Clinic
Terveystalo Oulu
Terveystalo Pulssi
Terveystalo Ruoholahti
Terveystalo Ruoholahti Helsinki
Terveystalo Sleep Clinic
Terveystalo Tampere
Terveystalo Turku
Turku

Clinical trials at this site (42)

Search interface

EFFICACY AND SAFETY OF GSK4527226 [AL101] IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE Ended

2023-505083-11-01 Alzheimer's Disease 4 2024-05-07
Study on immunogenicity and safety of a meningococcal ACYW conjugate vaccine in healthy infants and toddlers Ended

2023-508177-85-00 Healthy volunteers (Meningococcal infection) 5 2024-03-12
REIMAGINE 2: A research study to see how well CagriSema compared to semaglutide, cagrilintide and placebo lowers blood sugar and body weight… Ended

2022-502678-18-00 Type 2 diabetes 5 2023-11-07
A study to test whether spesolimab helps people with a skin disease called hidradenitis suppurativa Ended

2022-501074-19-00 Hidradenitis suppurativa 10 2023-10-13
A Multi-national Phase IIIb Trial to Determine the Safety and Efficacy of STALORAL® Birch 300 IR in Children and Adolescents 5 to 17 Years o… Ended

2023-509833-38-00 Birch Pollen-induced Allergic Rhinoconjunctivitis 5 2023-09-20
UNITAS Ended

2022-502483-21-00 Insomnia disorder 4 2023-07-28
A study to test whether spesolimab helps people with skin disease called Netherton syndrome Ended

2022-501104-10-00 Netherton syndrome (NS) 10 2023-06-06
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe AD (ROCKET-Horizon) Ended

2022-501538-44-00 Atopic Dermatitis 5 2023-04-25
Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease with a History of Exacerbations. Ended

2022-501063-41-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2023-04-20
C4951004 - BHV3000-406: A Phase 4, Randomized, Double-blind Placebo Controlled, Efficacy and Tolerability Trial of Rimegepant for the Acute … Ended

2024-513269-37-00 Migraine attacks with or without aura 6 2023-03-14
C4951012 - BHV3000-407: A Phase 4, Randomized, Double-blind, Placebo controlled Study to Evaluate the Efficacy and Tolerability of Rimegepan… Ended

2024-513270-21-00 migraine headaches with or without aura 6 2023-03-14
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Prospective, 52-Week, Phase 2 Clinical Study to Evaluate the S… Ended

2024-511610-20-00 Alzheimer's Disease 4 2022-11-08
Phase 3, Placebo-Controlled, Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Trial of a 6-Valent OspA-Based Lyme Disease… Ended

2023-509105-72-00 Active immunization against Lyme disease 5 2022-08-10
Study to assess efficacy, safety, and tolerability of Tozorakimab in patients with symptomatic chronic obstructive pulmonary disease (COPD) … Ended

2023-503571-19-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2022-01-20
A Trial to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents Ended

2024-512837-34-00 Episodic and Chronic Migraine 5 2020-10-14
An Open-Label, Multi-Center Extension Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects with Moderate-to-Sev… Ended

2022-502361-15-00 Moderate-to-Severe Plaque Psoriasis 5 2019-12-12
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Ended

2023-503673-38-00 Adults at high risk of cardiovascular events without pr 5 2019-05-24
Evaluation of Upadacitinib in Adolescent and Adult Patients with Moderate to Severe Atopic Dermatitis (Eczema)– Measure Up 1 Ended

2022-502938-30-00 Moderate and Severe Atopic Dermatitis 5 2018-12-10